Of 37 patients with matched T0-Tp samples in the HER2-2D cohort, 32 had received Trastuzumab (T) alone, or Trastuzumab plus Pertuzumab (T+P) for metastatic disease (Table 1) prior to T-DM1 treatment. This evidence concerns the gene ERBB2 and metastatic neoplasm.